10-Q and Current Reports on Form 8-K. All forward-looking statements made in this press release speak only as of the date of this press release and are based on management's assumptions and estimates as of such date. Except as required by law, Anebulo undertakes no obligation to update or revise forward-looking statements to reflect new information, future events, changed conditions or otherwise after the date of this press release.
Condensed Balance Sheets
December 31, June 30,
2024 2024
-------------- ----------
Cash and cash equivalents $ 14,998,467 $3,094,200
Total assets 15,841,220 4,073,114
Total liabilities 878,799 260,583
Total stockholders' equity 14,962,421 3,812,531
Condensed Statements of Operations
Three months ended December 31,
-----------------------------------
2024 2023
------------------ --------------
Research and development $ 1,220,535 $ 1,062,672
General and administrative 1,367,616 1,697,787
-------------- -------------
Total operating expenses 2,588,151 2,760,459
-------------- -------------
Loss from operations (2,588,151) (2,760,459)
Other (income) expenses:
Interest expense 59,696 31,838
Interest income (7,067) (75,522)
Grant income (177,703) -
Other (47) 594
-------------- -------------
Total other income, net (125,121) (43,090)
-------------- -------------
Net loss $ (2,463,030) $ (2,717,369)
============== =============
Weighted average common shares
outstanding, basic and
diluted 27,415,430 25,789,739
============== =============
Net loss per share, basic and
diluted $ (0.09) $ (0.11)
============== =============
View source version on businesswire.com: https://www.businesswire.com/news/home/20250214598365/en/
CONTACT: Anebulo Pharmaceuticals, Inc.
Daniel George
Chief Financial Officer
(512) 598-0931
Dan@anebulo.com
(END) Dow Jones Newswires
February 14, 2025 16:05 ET (21:05 GMT)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。